How profitable is Amneal Pharmaceuticals Inc. (AMRX)?

In FY 2025 (10-K), AMRX converted $3.0B of revenue into a 36.9% gross margin, 13.1% operating margin, and $269.9M in free cash flow (8.9% FCF margin).

Stock Ratings / Health Care / AMRX / financials

ABVX (54) AXSM (35) ALKS (78) KNSA (71) ⌘ Pro Terminal →

Amneal Pharmaceuticals Inc. (AMRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$20.44 -4.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.31

Amneal Pharmaceuticals Inc. (AMRX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (36.9% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $7.49B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $20.44 (-4.97% 1D, market cap $7.49B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AMRX ranks #67 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMRX compare to ABVX and AXSM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRX carries a Roarable B- (71/100 RQD), trailing P/E of 103.2x, gross margin of 36.9%, and ROIC of 14.1%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMRX?

▼

Per AMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723128), Amneal Pharmaceuticals Inc. generated $3.02B in revenue (+8.0% YoY), $72.1M in net income, and $269.9M in free cash flow against $3.68B in total assets and $2.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $20.31 (-0.65%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 8.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

3-of-3 Quant Analysts Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMRX)Realized 20D OHLCV Swing Band: ±5.8%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY AMRX SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)

20D Institutional Volume Accumulation (±5.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 3.83 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$18.90+6.9% Next Q

Q2 (-2Q)

Grade B-$20.20+4.7% Next Q

Q3 (-1Q)

Grade B-$21.14-3.3% Next Q

Current

Grade B-$20.44+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, AMRX faces multiple-compression risk if 103.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 103x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 34.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.33) or 200D SMA ($15.86) invalidates the momentum regime and cuts Target Base ($21.64) toward Bear Floor ($16.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AMRX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$269.9M (8.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.39B

FY24

Rev $2.79B

FY25

Rev $3.02B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$3.02B	36.9%	13.1%	$72.1M	$269.9M	14.1%
FY 2024	$2.79B	36.5%	8.9%	-$116.9M	$243.2M	10.1%
FY 2023	$2.39B	36.9%	8.5%	-$84.0M	$237.9M	6.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMRX)

✓Walkthrough of AMRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.91%📐 HORIZONTAL RANGE

2026-11-03O $21.35H $21.51L $20.44C $20.44VOL 2.77M

RES: $22.82SUP: $16.64SMA50: $19.33SMA200: $15.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMRX Butterfly Map → + Track AMRX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRX)

Health Care Rank #67 of 1015 ⚔️ ABVX vs AMRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMRX vs. ABVX, AXSM, ALKS, KNSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amneal Pharmaceuticals Inc. (AMRX) ranks #67 by composite RQD confidence (71/100, grade B-) and #130 by equity capitalization ($7.49B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with AMRX at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMRX ACTIVE Amneal Pharmaceuticals Inc.	B-	71/100	103.2x	36.9%	14.1%	-4.97%	$7.49B	Benchmark Subject
ABVX Abivax SA	D+	54/100	32.8x	—	9.9%	-1.94%	$7.56B	/abvx-vs-amrx →
AXSM Axsome Therapeutics Inc.	D-	35/100	—	—	-21.9%	-5.83%	$7.57B	/axsm-vs-amrx →
ALKS Alkermes plc	B+	78/100	31.5x	86.7%	14.0%	-0.99%	$7.61B	/alks-vs-amrx →
KNSA Kiniksa Pharmaceuticals International plc (Class A)	B-	71/100	129.9x	88.5%	9.9%	-1.56%	$7.25B	/knsa-vs-amrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001723128 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported GAAP revenue of $3.02B (+8.0% vs. FY2024 revenue of $2.79B , and +26.1% cumulative change since FY2023) , GAAP net income of $72.1M, operating cash flow of $340.0M, and free cash flow of $269.9M (+11.0% YoY). On the balance sheet, AMRX closed FY2025 with $3.68B in total assets against $2.57B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.02B	$72.1M	$340.0M	$269.9M	$3.68B	$2.57B
FY2024 (FY)	2024-12-31	$2.79B	-$116.9M	$295.1M	$243.2M	$3.50B	$2.16B
FY2023 (FY)	2023-12-31	$2.39B	-$84.0M	$345.6M	$237.9M	$4.09B	$957.0M

3. AMRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AMRX compare to ABVX and AXSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AMRX?

Where is AMRX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMRX last traded at $20.44 (-4.97% on volume of 5,019,747 shares), positioning the stock +5.74% above its 50-day simple moving average ($19.33) and +28.88% above its 200-day simple moving average ($15.86). Across its 52-week range of $10.68 to $21.68, AMRX sits at the 88.7% percentile with a 14-day RSI of 66.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($19.25 to $21.63).

Direct Sub-Reports: AMRX RQD Cockpit AMRX 12M Forecast AMRX Earnings & Move AMRX Dividends & DRIP AMRX Insiders & 13F AMRX Whale Options AMRX Profit Sankey AMRX News & Why

ROARABLE RATING BRIEF • RQD 71/100 (B-) ✓ SEC XBRL & RQD VERIFIED

AMRX — Amneal Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amneal Pharmaceuticals Inc. (AMRX) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $20.44 (-4.97% 1D, market capitalization $7.49B).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 14.1%, gross margin of 36.9%, operating margin of 13.1%, and free cash flow yield of 3.63%.
Whale 13F & Options Flow (17/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.08x equity beta, Altman Z-Score of 3.83, Piotroski F-Score of 9/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amneal Pharmaceuticals Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Specific product lines, customer base, and revenue model details are — The company's scale is reflected in its $7.44B market capitalization and reported FY 2025 revenue of $3.02B, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported $3.02B in annual revenue (up from $2.79B in FY2024, +8.0% YoY) and $72.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.39B revenue, -$84.0M net income) through FY2025, AMRX scaled operating cash flow to $340.0M and free cash flow to $269.9M, backed by $3.68B in total assets against $2.57B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B- • RQD 71/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $10.68 – $21.68 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 103.2x trailing P/E and 21.4x EV/EBITDA against 13.1% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or bottleneck links are recorded (supply chain: NONE; butterfly links: empty). Specific upstream supplier and downstream customer relationships are — A prospective investor should monitor the Q3 earnings release and any valuation-driven volatility identified in the news feed, as these are the nearest-term signals in the available data.

Key Question #1: Can AMRX sustain or expand its 13.1% operating margin and 14.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $3.02B and free cash flow of $269.9M, how will capital allocation balance growth reinvestment against $2.57B in total debt?
Key Question #3: How sensitive is AMRX's 96.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

AMRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amneal Pharmaceuticals Inc. (AMRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMRX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 1d ago

Amneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth Concerns

Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Zacks Investment Research • 1d ago

Implied Volatility Surging for Amneal Pharmaceuticals Stock Options

Zacks Investment Research report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Amneal (AMRX) Q3 earnings: what to expect

TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 2d ago

Why Amneal Pharmaceuticals (AMRX) Is Getting Attention Now

Simply Wall St report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Amneal Pharmaceuticals, Inc. Estimates – NASDAQ:AMRX

TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

Where Does Amneal Pharmaceuticals (AMRX) Value Sit After A 4.4x Run?

Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockStory • 2d ago

1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds

StockStory report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMRX Bull vs. Bear Conversation Board — What's Your Call at $20.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMRX 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $26.67 (+24.0%)

📌 Pinned Debate

Institutional whale-flow (18/20) and a strong forensic balance sheet (Altman Z 3.83, Piotroski F 9/9) support the B-grade Buy rating.

Here is why I am bullish on AMRX here at $21.51: Institutional whale-flow (18/20) and a strong forensic balance sheet (Altman Z 3.83, Piotroski F 9/9) support the B-grade Buy rating.. Compare AMRX's 13.1% operating margin and 14.1% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $20.43 are getting bought.

EarningsSniper 🐂 BULL

@ForensicBear Shorting a 17/20 institutional whale-flow stock at $21.51 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $16.35 (-24.0%)

Spot @ $21.51

Trailing P/E of 103.2 against a 2.4% net margin and $0.21 EPS leaves the stock priced for growth that the reported earnings do not yet

Trailing P/E of 103.2 against a 2.4% net margin and $0.21 EPS leaves the stock priced for growth that the reported earnings do not yet show.. Look at the math on AMRX: paying 103.2x trailing P/E for 14.1% ROIC and 13.1% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $18.93 before getting long.